|
1
|
Group IMW; International Myeloma Working
Group, : Criteria for the classification of monoclonal
gammopathies, multiple myeloma and related disorders: A report of
the International Myeloma Working Group. Br J Haematol.
121:749–757. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kumar SK, Rajkumar SV, Dispenzieri A, Lacy
MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust
JA, et al: Improved survival in multiple myeloma and the impact of
novel therapies. Blood. 111:2516–2520. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pulte D, Gondos A and Brenner H:
Improvement in survival of older adults with multiple myeloma:
Results of an updated period analysis of SEER data. Oncologist.
16:1600–1603. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brenner H, Gondos A and Pulte D: Expected
long-term survival of patients diagnosed with multiple myeloma in
2006–2010. Haematologica. 94:270–275. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kumar SK, Lee JH, Lahuerta JJ, Morgan G,
Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau
P, et al International Myeloma Working Group, : Risk of progression
and survival in multiple myeloma relapsing after therapy with IMiDs
and bortezomib: A multicenter international myeloma working group
study. Leukemia. 26:149–157. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tai YT, Li X, Tong X, Santos D, Otsuki T,
Catley L, Tournilhac O, Podar K, Hideshima T, Schlossman R, et al:
Human anti-CD40 antagonist antibody triggers significant antitumor
activity against human multiple myeloma. Cancer Res. 65:5898–5906.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bae J, Prabhala R, Voskertchian A, Brown
A, Maguire C, Richardson P, Dranoff G, Anderson KC and Munshi NC: A
multiepitope of XBP1, CD138 and CS1 peptides induces
myeloma-specific cytotoxic T lymphocytes in T cells of smoldering
myeloma patients. Leukemia. 29:218–229. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rosenblatt J, Avivi I, Vasir B, Uhl L,
Munshi NC, Katz T, Dey BR, Somaiya P, Mills H, Campigotto F, et al:
Vaccination with dendritic cell/tumor fusions following autologous
stem cell transplant induces immunologic and clinical responses in
multiple myeloma patients. Clin Cancer Res. 19:3640–3648. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hong S, Li H, Qian J, Yang J, Lu Y and Yi
Q: Optimizing dendritic cell vaccine for immunotherapy in multiple
myeloma: Tumour lysates are more potent tumour antigens than
idiotype protein to promote anti-tumour immunity. Clin Exp Immunol.
170:167–177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Anderson LD Jr, Cook DR, Yamamoto TN,
Berger C, Maloney DG and Riddell SR: Identification of MAGE-C1
(CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer
Immunol Immunother. 60:985–997. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Michalek J, Ocadlikova D, Matejkova E,
Foltankova V, Dudová S, Slaby O, Horvath R, Pour L and Hajek R:
Individual myeloma-specific T-cell clones eliminate tumour cells
and correlate with clinical outcomes in patients with multiple
myeloma. Br J Haematol. 148:859–867. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou FL, Zhang WG, Chen G, Zhao WH, Cao
XM, Chen YX, Tian W, Liu J and Liu SH: Serological identification
and bioinformatics analysis of immunogenic antigens in multiple
myeloma. Cancer Immunol Immunother. 55:910–917. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lamesch P, Li N, Milstein S, Fan C, Hao T,
Szabo G, Hu Z, Venkatesan K, Bethel G, Martin P, et al: hORFeome
v3.1: A resource of human open reading frames representing over
10,000 human genes. Genomics. 89:307–315. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gonzalez-Begne M, Lu B, Han X, Hagen FK,
Hand AR, Melvin JE and Yates JR: Proteomic analysis of human
parotid gland exosomes by multidimensional protein identification
technology (MudPIT). J Proteome Res. 8:1304–1314. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Redman KL and Rechsteiner M:
Identification of the long ubiquitin extension as ribosomal protein
S27a. Nature. 338:438–440. 1989. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shabek N and Ciechanover A: Degradation of
ubiquitin: The fate of the cellular reaper. Cell Cycle. 9:523–530.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Komander D, Clague MJ and Urbé S: Breaking
the chains: Structure and function of the deubiquitinases. Nat Rev
Mol Cell Biol. 10:550–563. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Adams SM, Sharp MG, Walker RA, Brammar WJ
and Varley JM: Differential expression of translation-associated
genes in benign and malignant human breast tumours. Br J Cancer.
65:65–71. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wong JM, Mafune K, Yow H, Rivers EN,
Ravikumar TS, Steele GD Jr and Chen LB: Ubiquitin-ribosomal protein
S27a gene overexpressed in human colorectal carcinoma is an early
growth response gene. Cancer Res. 53:1916–1920. 1993.PubMed/NCBI
|
|
21
|
Kanayama H, Tanaka K, Aki M, Kagawa S,
Miyaji H, Satoh M, Okada F, Sato S, Shimbara N and Ichihara A:
Changes in expressions of proteasome and ubiquitin genes in human
renal cancer cells. Cancer Res. 51:6677–6685. 1991.PubMed/NCBI
|
|
22
|
Vincent Rajkumar S: Multiple myeloma: 2014
update on diagnosis, risk-stratification, and management. Am J
Hematol. 89:999–1009. 2014.PubMed/NCBI
|
|
23
|
Tarkun P, Atalay F, Atesoglu EB, Mehtap O,
Simsek M, Terzi E, Geduk A, Balli F, Batman A, Baydemir C, et al:
Treatment of patients with multiple myeloma over 65 yr: More
tolerability or better response? Eur J Haematol. 94:424–430. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chim CS, Sim J, Tam S, Tse E, Lie AK and
Kwong YL: LDH is an adverse prognostic factor independent of ISS in
transplant-eligible myeloma patients receiving bortezomib-based
induction regimens. Eur J Haematol. 94:330–335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kiba T, Ito T, Nakashima T, Okikawa Y,
Kido M, Kimura A, Kameda K, Miyamae F, Tanaka S, Atsumi M, et al:
Bortezomib and dexamethasone for multiple myeloma: Higher AST and
LDH levels associated with a worse prognosis on overall survival.
BMC Cancer. 14:4622014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tricot G, Barlogie B, Jagannath S, Bracy
D, Mattox S, Vesole DH, Naucke S and Sawyer JR: Poor prognosis in
multiple myeloma is associated only with partial or complete
deletions of chromosome 13 or abnormalities involving 11q and not
with other karyotype abnormalities. Blood. 86:4250–4256.
1995.PubMed/NCBI
|
|
27
|
Fonseca R, Barlogie B, Bataille R, Bastard
C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR,
et al: Genetics and cytogenetics of multiple myeloma: A workshop
report. Cancer Res. 64:1546–1558. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fonseca R, Blood E, Rue M, Harrington D,
Oken MM, Kyle RA, Dewald GW, van Ness B, van Wier SA, Henderson KJ,
et al: Clinical and biologic implications of recurrent genomic
aberrations in myeloma. Blood. 101:4569–4575. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Facon T, Avet-Loiseau H, Guillerm G,
Moreau P, Geneviève F, Zandecki M, Laï JL, Leleu X, Jouet JP,
Bauters F, et al: Intergroupe Francophone du Myélome: Chromosome 13
abnormalities identified by FISH analysis and serum
beta2-microglobulin produce a powerful myeloma staging system for
patients receiving high-dose therapy. Blood. 97:1566–1571. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oh S, Koo DH, Kwon MJ, Kim K, Suh C, Min
CK, Yoon SS, Shin HJ, Jo DY, Kwak JY, et al: Korean Multiple
Myeloma Working Party (KMMWP): Chromosome 13 deletion and
hypodiploidy on conventional cytogenetics are robust prognostic
factors in Korean multiple myeloma patients: Web-based multicenter
registry study. Ann Hematol. 93:1353–1361. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kyrtsonis MC, Maltezas D, Tzenou T,
Koulieris E and Bradwell AR: Staging systems and prognostic factors
as a guide to therapeutic decisions in multiple myeloma. Semin
Hematol. 46:110–117. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Younes M, Hachfi H, Hammouda F, Younes K,
Ben Hammouda S, Jguirim M, Zrour S, Béjia I, Touzi M and Bergaoui
N: Survival prognosis factors in multiple myeloma. Tunis Med.
92:399–405. 2014.(In French). PubMed/NCBI
|
|
33
|
Lohr JG, Stojanov P, Carter SL,
Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B,
Gould J, Saksena G, et al: Multiple Myeloma Research Consortium:
Widespread genetic heterogeneity in multiple myeloma: Implications
for targeted therapy. Cancer Cell. 25:91–101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Levine AJ: p53, the cellular gatekeeper
for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Drach J, Ackermann J, Fritz E, Krömer E,
Schuster R, Gisslinger H, DeSantis M, Zojer N, Fiegl M, Roka S, et
al: Presence of a p53 gene deletion in patients with multiple
myeloma predicts for short survival after conventional-dose
chemotherapy. Blood. 92:802–809. 1998.PubMed/NCBI
|
|
36
|
Königsberg R, Zojer N, Ackermann J, Krömer
E, Kittler H, Fritz E, Kaufmann H, Nösslinger T, Riedl L,
Gisslinger H, et al: Predictive role of interphase cytogenetics for
survival of patients with multiple myeloma. J Clin Oncol.
18:804–812. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chang H, Qi C, Yi QL, Reece D and Stewart
AK: p53 gene deletion detected by fluorescence in situ
hybridization is an adverse prognostic factor for patients with
multiple myeloma following autologous stem cell transplantation.
Blood. 105:358–360. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nosrati N, Kapoor NR and Kumar V: DNA
damage stress induces the expression of ribosomal protein S27a gene
in a p53-dependent manner. Gene. 559:44–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun XX, DeVine T, Challagundla KB and Dai
MS: Interplay between ribosomal protein S27a and MDM2 protein in
p53 activation in response to ribosomal stress. J Biol Chem.
286:22730–22741. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Warner JR and McIntosh KB: How common are
extraribosomal functions of ribosomal proteins? Mol Cell. 34:3–11.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wool IG: Extraribosomal functions of
ribosomal proteins. Trends Biochem Sci. 21:164–165. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gertz MA, Lacy MQ, Dispenzieri A, Greipp
PR, Litzow MR, Henderson KJ, van Wier SA, Ahmann GJ and Fonseca R:
Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and
−17p13 in myeloma patients treated with high-dose therapy. Blood.
106:2837–2840. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
van de Donk NW and Sonneveld P: Diagnosis
and risk stratification in multiple myeloma. Hematol Oncol Clin
North Am. 28:791–813. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mangiacavalli S, Pochintesta L, Cocito F,
Pompa A, Bernasconi P, Cazzola M and Corso A: Correlation between
burden of 17P13.1 alteration and rapid escape to plasma cell
leukaemia in multiple myeloma. Br J Haematol. 162:555–558. 2013.
View Article : Google Scholar : PubMed/NCBI
|
